Annual Accounts Payable
$3.95 M
-$633.00 K-13.80%
December 31, 2023
Summary
- As of February 12, 2025, RXRX annual accounts payable is $3.95 million, with the most recent change of -$633.00 thousand (-13.80%) on December 31, 2023.
- During the last 3 years, RXRX annual accounts payable has risen by +$2.88 million (+268.06%).
- RXRX annual accounts payable is now -13.80% below its all-time high of $4.59 million, reached on December 31, 2022.
Performance
RXRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$2.26 M
-$1.50 M-39.93%
September 30, 2024
Summary
- As of February 12, 2025, RXRX quarterly accounts payable is $2.26 million, with the most recent change of -$1.50 million (-39.93%) on September 30, 2024.
- Over the past year, RXRX quarterly accounts payable has dropped by -$2.85 million (-55.82%).
- RXRX quarterly accounts payable is now -64.27% below its all-time high of $6.33 million, reached on September 30, 2021.
Performance
RXRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
RXRX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.8% | -55.8% |
| 3 y3 years | +268.1% | -50.7% |
| 5 y5 years | +213.5% | -50.7% |
RXRX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -13.8% | +40.2% | -55.8% | +8.3% |
| 5 y | 5-year | -13.8% | +268.1% | -64.3% | +110.4% |
| alltime | all time | -13.8% | +268.1% | -64.3% | +110.4% |
Recursion Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.26 M(-39.9%) |
| Jun 2024 | - | $3.76 M(-26.5%) |
| Mar 2024 | - | $5.12 M(+29.4%) |
| Dec 2023 | $3.95 M(-13.8%) | $3.95 M(-7.3%) |
| Sep 2023 | - | $4.26 M(+104.5%) |
| Jun 2023 | - | $2.09 M(-50.9%) |
| Mar 2023 | - | $4.25 M(-7.4%) |
| Dec 2022 | $4.59 M | $4.59 M(+17.9%) |
| Sep 2022 | - | $3.89 M(+22.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $3.18 M(-23.7%) |
| Mar 2022 | - | $4.16 M(+47.6%) |
| Dec 2021 | $2.82 M(+162.5%) | $2.82 M(-55.4%) |
| Sep 2021 | - | $6.33 M(+97.9%) |
| Jun 2021 | - | $3.20 M(+2.3%) |
| Mar 2021 | - | $3.13 M(+191.0%) |
| Dec 2020 | $1.07 M(-14.8%) | - |
| Dec 2020 | - | $1.07 M |
| Dec 2019 | $1.26 M | - |
FAQ
- What is Recursion Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual accounts payable year-on-year change?
- What is Recursion Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly accounts payable year-on-year change?
What is Recursion Pharmaceuticals annual accounts payable?
The current annual accounts payable of RXRX is $3.95 M
What is the all time high annual accounts payable for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual accounts payable is $4.59 M
What is Recursion Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, RXRX annual accounts payable has changed by -$633.00 K (-13.80%)
What is Recursion Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of RXRX is $2.26 M
What is the all time high quarterly accounts payable for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly accounts payable is $6.33 M
What is Recursion Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, RXRX quarterly accounts payable has changed by -$2.85 M (-55.82%)